RECRUITING

Depo-Medrol on Psoas After LLIF

Description

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

Conditions

Muscle WeaknessPain, PostoperativeParesthesiaPain, Muscle
Talk to us

Related Conditions:

Muscle WeaknessPain, PostoperativeParesthesiaPain, Muscle

Study Overview

On this page

Study Details

Study overview

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness

Depo-Medrol on Psoas After LLIF

Condition
Muscle Weakness
Intervention / Treatment

-

Contacts and Locations

Farmington

UConn Health, Farmington, Connecticut, United States, 06030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients from the practices of Drs. Singh, Mallozzi, Moss
  • * Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and/or L4-5
  • * Patients who agree to be a part of the study
  • * Patients with lumbar disc degeneration
  • * Patients between ages of 18 and 75
  • * Scoliosis \>10°
  • * Spondylolisthesis \>Grade 1
  • * Flatback deformity
  • * Patients with insulin dependent diabetes
  • * Patients with \>3 levels of fusion
  • * Alternative interbodies
  • * Chronic oral steroid users
  • * Patients with allergy/intolerance to depo-medrol or other steroids
  • * Patients requiring bilateral transpsoas approaches
  • * Patients with ipsilateral symptomatic hip pathology
  • * Revision fusion procedures
  • * Cases involving trauma, tumor, or infection
  • * Patient's not capable of providing consent themselves
  • * Non-fluent English speakers (for consenting reasons)
  • * Patients who are lost to follow-up before the two year follow up period

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Hardeep Singh,

Hardeep Singh, M.D., PRINCIPAL_INVESTIGATOR, UConn Health

Study Record Dates

2027-05